A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.
Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y, Namiki S, Fujimoto K, Kawanishi H, Sato F, Narita S, Satoh T, Saito H, Sugimoto M, Teishima J, Masumori N, Egawa S, Sakai H, Okada Y, Terachi T, Ogawa O; ZAPCA Study Group.
Kamba T, et al. Among authors: sugimoto m.
Int J Clin Oncol. 2017 Feb;22(1):166-173. doi: 10.1007/s10147-016-1037-2. Epub 2016 Sep 10.
Int J Clin Oncol. 2017.
PMID: 27614621
Clinical Trial.